Fingerprint
Dive into the research topics of 'Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma
Neehar D. Parikh, Amit G. Singal, David W. Hutton
Research output: Contribution to journal › Article › peer-review
61
Scopus
citations